Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Time to Buy?

by · The Markets Daily

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) saw unusually-high trading volume on Thursday. 603,075 shares changed hands during trading, an increase of 152% from the previous session’s volume of 238,886 shares. The stock last traded at $19.51 and had previously closed at $19.57.

Wall Street Analysts Forecast Growth

CHGCY has been the subject of several analyst reports. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Chugai Pharmaceutical currently has a consensus rating of “Moderate Buy”.

Check Out Our Latest Report on CHGCY

Chugai Pharmaceutical Stock Down 0.5%

The company has a market cap of $64.12 billion, a PE ratio of 21.17 and a beta of 0.59. The business’s fifty day moving average is $21.41 and its 200-day moving average is $23.78.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last released its earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. Analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.

See Also